In patients with moderate-to-severe asthma, the treatment with dupilumab, an anti-IL-4Rα antibody, efficiently reduces severe exacerbation and improves lung functions (97), suggesting the involvement of IL-4 and/or IL-13 in the pathogenesis of asthma. This evidence concerns the gene IL13 and asthma.